Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma—Case Report and Review of the Literature

Anli Tong¹, Ming Li², Yunying Cui¹, Xiaosen Ma¹, Huiping Wang¹ and Yuxiu Li¹*

¹ Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People’s Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, ² Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

Context: Metastatic pheochromocytoma/paraganglioma (MPP) therapy mainly involves radionuclide therapy, chemotherapy, and targeted therapy. In recent years, temozolomide (TMZ) showed great promise in some MPP patients, especially those with SDHB germline mutation. We reported a patient with MPP who did not have any known germline genetic change and responded remarkably well to TMZ monotherapy.

Case presentation: The patient was a 41-year-old woman with local and distant recurrence (soft tissues and bone metastases) of retroperitoneal paraganglioma. She suffered from dizziness, palpitation, sweating, weight loss and constipation, with the blood pressure fluctuating substantially from 130/100 mmHg to 190/120 mmHg, although she was on phenoxybenzamine and metoprolol medication. The patient showed clinical and radiological response after 3-cycle TMZ therapy. Upon 15 cycles of TMZ therapy, her symptoms were dramatically alleviated, urinary norepinephrine excretion decreased from 1,840 µg/24 h to 206 µg/24 h, and CT showed that the lesions further shrank. Molecular profiling of the tumor tissue of the patient revealed hypermethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter and a negative immunostaining for MGMT. Globally, only 26 cases of MPP treated with TMZ have been described so far. TMZ is effective, especially in patients with SDHB mutation, which can be explained by the silencing of MGMT expression as a consequence of MGMT promoter hypermethylation in SDHB-mutated tumors. Although, in general, patients with SDHB mutation or MGMT promoter hypermethylation have better response to TMZ, there are also exceptions. Severe side effects are uncommon, with only 17.4% patients experiencing Grade 3 toxicities, including lymphopenia, and hypertension.
Conclusions: TMZ is effective and safe in MPP patients, and, it may work better on patients with SDHB-related MPP. Measurement of MGMT expression might help assess the tumor sensitivity to TMZ but this needs further systematic investigation.

Keywords: metastatic pheochromocytoma/paraganglioma, therapy, temozolomide, DNA Methylation, SDHB

INTRODUCTION

Pheochromocytoma (PHEO) and paraganglioma (PGL) are rare tumors originating from adrenal medulla, sympathetic paravertebral ganglia, and parasympathetic ganglia. Metastatic pheochromocytoma/paraganglioma (MPP), defined as metastasis in non-chromophilic tissues, such as lymph nodes, bone, liver, lung, etc, accounts for 10–17% of all PHEO/PGL. Metastasis in MPP, mostly multiple and invasive, usually could not be completely resected, and the mean overall 5-year survival rate of the patients is 44% (1).

The first and most important treatment for MPP is surgery. But for the non-resectable tumors and metastatic loci, second line therapy includes systemic treatment, such as radionuclide therapy, chemotherapy and targeted therapy, and local treatment, such as radiotherapy, ablation and embolization. Radionuclide therapy includes 131I-MIBG therapy and peptide receptor radionuclide therapy (PRRT, such as 177Lu-DOTATATE), which can only be used for the treatment of tumors with uptake of the tracer (2, 3). Molecular targeted therapy, such as sunitinib, has shown great potential in the treatment of MPP, but needs to be further investigated (4). Chemotherapy mainly includes CVD regimen (cyclophosphamide, vincristine, and dacarbazine) and temozolomide (TMZ) (5, 6). CVD is the most commonly used chemotherapeutic regimen for MPP (7), and TMZ, an oral alkylation chemotherapeutic agent, was first reported to be used for the treatment of MPP in 2006 (8). Because MPP is relatively rare, so far, only 26 cases of MPP were reportedly treated with TMZ, most of them being presented in the form of case reports (8–15). TMZ was effective in MPP patients, especially those with SDHB germline mutation (12). Although in glioblastoma, the efficacy of TMZ is strongly related to the level of O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation (16), it is not clear whether a similar relationship exists in MPP.

In this report, we presented a Chinese MPP patient who responded fairly well to TMZ monotherapy. This patient did not have any known germline genetic change. The efficacy and safety of TMZ therapy in MPP were also discussed at length in the paper.

CASE PRESENTATION

In June 2018, a 41-year-old woman presented to the Peking Union Medical College Hospital, Beijing, China. In 2015, she had episodes of headache, palpitation, and sweating. Her blood pressure was 200/120 mmHg. Imaging studies revealed a retroperitoneal mass of about 8 cm in size. In November 2015, she underwent surgical resection and the mass was pathologically diagnosed as PGL. Postoperatively, her symptoms, and hypertension were relieved.

Two years later, her blood pressure again rose to 150–160/100 mmHg. The patient was found to have multifocal bone lesions on contrast-enhanced computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). In March 2018, the patients underwent 131I-meta-iodobenzyl-guanidine (131I-MIBG) therapy at a dose of 200 mCi. Post-treatment scintigraphy suggested uptake of 131I-MIBG to most metastatic lesions was unsatisfactory.

In June 2018, the patient was referred to our hospital. She suffered from dizziness, palpatation, sweating, weight loss and constipation, although she was on phenoxybenzamine 20 mg q8h and metoprolol 25 mg tid. The blood pressure fluctuated greatly from 130/100 to 190/120 mmHg. Urinary norepinephrine excretion was 1,804 µg/24 h [reference value (r.v.): 17–41 µg/24 h], urinary epinephrine was 4 µg/24 h (r.v.: 2–6 µg/24 h), and dopamine was 203 µg/24 h (r.v.: 121–331 µg/24 h) (Figure 1). CT scan showed multiple high-intensity nodules below and latero-posterior to right kidney and below and below to duodenal horizontal segment (Figure 2). Multiple bony defects were found in lumbar vertebrae, sacrum and iliac bones, suggesting metastases. She was put on sunitinib at 37.5 mg daily from July 2018. After 3 months of treatment, her hypertension deteriorated, with blood pressure being 180/120 mmHg even at 100 mg of phenoxybenzamine and 75 mg of metoprolol on daily basis. Her urinary catecholamine did not decrease, with norepinephrine excretion being 1,840 µg/24 h, dopamine was 258 µg/24 h and epinephrine 1,400 µg/24 h (Figure 1). CT showed that some of the aforementioned lesions enlarged (Figure 2).

In Oct 2018, the patient was put on TMZ at 150 mg/m²/d on days 1–5 in a 28-day cycle. In the second and the following cycles, she took TMZ at 200 mg/m²/d (on a 5/28-day regimen). After three cycles, blood pressure of the patient dropped significantly, and CT suggested that the lesions were significantly diminished (Figure 2). After nine cycles, her symptoms, including dizziness, palpitation, sweating and constipation, were dramatically alleviated, and at reduced-dose of phenylbenzylamine (10 mg q8h) and metoprolol (25 mg bid), her blood pressure was lowered to 130-150/90-100 mmHg. After fifteen cycles, her blood pressure decreased further and was 120-130/70-80 mmHg on phenylbenzylamine (5 mg q12h) and metoprolol (12.5 mg bid). Urinary norepinephrine excretion decreased to 206 µg/24 h, epinephrine was 5 µg/24 h and dopamine was 258 µg/24 h. Serum neuron-specific enolase (NSE) was 35.1 ng/ml (r.v.: 0–16.0 ng/ml) (Figure 1). CT showed that some of the aforementioned lesions enlarged (Figure 2).
Tong et al. Temozolomide Is Effective for MPP

FIGURE 1 | Biochemical responses of the patient to TMZ therapy. NE, norepinephrine; NSE neuronspecific enolase.

FIGURE 2 | Radiological responses of the patient to TMZ therapy.

the medication. No bone marrow suppression was observed. Written informed consent for data publication was obtained from the patient.

Genetic Detection
Genetic screening of the genomic DNA from peripheral blood leukocytes of the patient was conducted by using targeted next-generation sequencing (NGS) that involved 20 genes (NF1, VHL, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, MAX, TMEM127, FH, KIF1B, BAP1, IDH1, EPAS1, EGLN2, EGLN1, EGLN3, HRAS, MDH2), and the sequencing failed to identify any pathogenic genetic change (Supplement 1). Large deletions of SDHB, SDHC, SDHD, SDHAF2, and VHL were excluded by MLPA using a MLPA reagent kit (MRC-Holland) (Supplement 2).

Pathological Features and Immunohistochemistry
Hematoxylin-eosin staining showed that the tumor cells were arranged in nest-like pattern, having basophil cytoplasm, and large nuclei. The tumor tissues were immunohistochemically examined by using the EnVision detection kit and was found to be negative for MGMT and positive for SDHB, with a Ki-67 index of 1% (Figure 3).

MGMT Methylation Analysis
Methylation of four CpG sites in exon 1 of the human MGMT gene was quantitatively determined by employing the MGMT Pyrosequencing, and the results showed that the four sites were hypermethylated (Supplement 2).

DISCUSSION
MPP accounted for 10–17% in all PHEO/PGL cases. Compared with PHEO, PGL is more prone to metastasis. Five to twenty percent of PHEO and 15–35% of sympathetic PGL metastasize (17). Thirty five to forty percent of patients with PHEO/PGL have germline genetic mutation, and the rate is 50% in patients with MPP. So far, over twenty genes associated with PGL hereditary
syndromes have been reported. Mutations in SDHB are one of the most common causes of familial PHEO/PGL, and tend to be associated with MPPs, particularly MPPs that afflict younger patients (18, 19). The patient in our study did not have any known germline genetic change, including such genes related to MPP as SDHB and FH.

TMZ is widely used for the treatment of various tumors, such as adult refractory pleomorphic glioblastoma, anaplastic astrocytoma, pancreatic neuroendocrine neoplasm and invasive pituitary tumor and pituitary cancer (16, 20, 21). The cytotoxic activities of TMZ lies in DNA methylation and failure of mismatch repair (22, 23). TMZ resistance is mediated predominantly by MGMT protein. MGMT is a highly-efficient DNA repair enzyme, which can repair methylated DNA. Tumor cells lacking MGMT expression are significantly more sensitive to the cytotoxic effects of TMZ than their counterparts expressing functional MGMT (22, 23).

Only 26 patients have been reported to be treated by TMZ since 2006 (8–15). The two earliest studies examined MPP and other neuroendocrine tumors at the same time, and they didn’t elaborate on the therapeutic effect of TMZ in MPP patients (8, 9). Therefore, in this paper, we reviewed the efficacy and safety of TMZ therapy in 23 MPP patients whose data were relatively complete (Table 1) (10–15). Except a retrospective study involving 15 patients with progressive MPP treated with TMZ, reported by Hadoux et al. (12), all the others were case reports. Most patients, just like our patient, received TMZ therapy at a dose of 150–200 mg/m² (orally, once daily) on days 1–5 and the medication was repeated every 28 days, as it is used for glioblastoma patients. Two patients were given TMZ at a dose of 75 mg/m²/d for 3 weeks and were taken off the treatment for one week (21/28-day regimen) (13, 14). The total dosages of the two strategies were similar in each treatment cycle.

Hadox et al. found that, of 15 MPP patients in their series on TMZ therapy, 5 (33%) achieved partial response (PR), 7 (47%) had stable disease (SD) and 3 (20%) suffered from progressive disease (PD). Ten patients had a SDHB germline mutation. Of these 10 patients, 9 patients were PR + SD and only 1 was PD. PFS was significantly longer in patients with SDHB mutation than in patients without mutations (19.7 vs. 2.9 months), 80% of PR patients exhibited MGMT deficiency (12). In a separate cohort involving 190 PHEO/PGLs, SDHB mutation was associated with hypermethylation of the MGMT promoter and low expression of MGMT (12). This study demonstrated that TMZ was an effective antitumour agent for patients with SDHB-related MPP. And the result can be explained by the silencing of MGMT expression as a consequence of MGMT promoter hypermethylation in SDHB-mutated tumors (12). However, some other studies showed that, like our case, TMZ was also effective in patients with non-SDHB mutations. Tumors carrying mutations in Krebs cycle-related genes, such as SDHx and FH, exhibit CpG island hypermethylation, which was caused by the accumulation of specific metabolites. These metabolites lead to inactivation of DNA demethylases and thus to epigenetic alterations in the genome which leads to global gene expression changes, including loss of MGMT expression (24, 25). Our patient did not have any known germline pathogenic genetic change, but showed MGMT promoter hypermethylation, suggesting that other factors might also contribute DNA hypermethylation. Since the lesions of our patient shrank dramatically after TMZ treatment, we were led to speculate that MGMT promoter hypermethylation is ubiquitous in tumor tissues, and the factors causing hypermethylation exist in the early stage of the tumor development.

MGMT was expressed in tumor tissue of a patient with SDHB germline mutation (patient 8 in Table 1) (12). This patient had a PR for 30 months on TMZ, which suggested that TMZ might be effective for some patients even if MGMT was intact. In contrast, in a patient with both SDHB mutation and MGMT promoter hypermethylation (patient 6), the partial response to TMZ lasted only 8 month (11). Other two patients with SDHB mutation (patient 9 and patient 14) even had PD after TMZ treatment (12). These cases suggest that assessing the response to TMZ is very complex. And there is mixed evidence about the topic. In general, patients with SDHB mutation or MGMT promoter hypermethylation respond better to TMZ. Correlation between MGMT promoter methylation and overall survival has been studied intensively in patients with both glioblastoma and neuroendocrine neoplasm. Patients whose tumors carried a methylated MGMT promoter benefited more from TMZ treatment. Determination of the MGMT methylation status is recommended as a predictive biomarker of response in these patients (5, 26–28). However, in patients with MPP, due to the limited cases reported till now, it is still early to jump into a conclusion. Well-designed prospective clinical trials are needed to clarify the correlation between the level of MGMT promoter methylation and effectiveness of TMZ.

Two MPP patients were treated with TMZ in combination with capecitabine (patient 2 and patient 6 in Table 1) (11, 14). The combination therapy of TMZ and capecitabine has been widely used, and in recent years, it has emerged as the most promising and efficacious treatment for pancreatic neuroendocrine neoplasms. Capecitabine transforms into 5-FU in tumor tissues, and its metabolites can reduce the
| Pt | Sex/age | Gene mutation | MGMT methylation | MGMT expression | Location of mass | Prior treatment/ PFS (mo)/ effect | TMZ doses/ cycles | Combination of other therapy | CgA response | MNs response | RECIST 1.1 | PERCIST 1.0 | Duration of TMZ | Side effect | References |
|----|---------|---------------|------------------|-----------------|-----------------|---------------------------------|-----------------|-----------------------------|--------------|--------------|------------|-------------|----------------|-------------|------------|
| 1  | M/60    | SDHB          | Yes              | NA              | Bone and soft tissue metastases | Sunitinib/2/ PD, Lanreotide/ CVD/6/PD | 75 mg/m² (2/28)/17, 75 mg/m² (21/35)/10 | Lanreotide 120 mg q2w, Zoledronic acid 4 mg q4w | Stable        | Response³  | NA         | PMR         | 27 cycles       | Grade 3 lymphopenia | (14)       |
| 2  | F/46    | SDHB          | Yes              | NA              | Bone and soft tissue metastases | CVD/8/PD, Lanreotide/ 15/PD | 200 mg/m² (5/28)/4, 75 mg/m² (21/28)/7 | Capecitabine 750 mg/m² bid (14/28)/4, Denosumab 120 mg q2w, Lanreotide 120 mg q2w/7 | Response Normal⁵ | NA         | NA         | PMR         | 13 cycles       | No side effect                | (14)       |
| 3  | M/51    | ND⁰           | Yes              | NA              | Recurrence of PCC, liver and bone metastases | Sunitinib/ 4/PD | 150 mg/m² (5/28) | No | NA         | Response Normal⁵ | PR          | NA         | 24 cycles       | Grade 2 thrombocytopenia | (15)       |
| 4  | F/54    | MAX           | NA               | NA              | Unresectable PGL | Sunitinib/4d | 150 mg/m² (5/28) | No | NA         | Stable        | SD          | NA         | 23 cycles       | No grade 3–4 side effects | (15)       |
| 5  | M/53    | SDHA          | NA               | NA              | Bone metastases | Lanreotide+ denosumab/18/PD | 75 mg/m²/d (21/28) | Propranolol 3 mg/kg/d | Decrease²  | Decrease²  | NA         | PMR         | 14 cycles       | Lymphopenia and thrombocytopenia | (13)       |
| 6  | M/57    | SDHB          | Yes              | NA              | Lymph nodes and lung metastases | Gemcitabine+200 mg/m² oxaliplatin/8d | 200 mg/m² (5/28) | Capcitabine 750 mg/m² bid (14/28) | NA         | NA         | PR          | NA         | 8 cycles       | NA         | (11)       |
| 7  | F/60    | NA            | NA               | NA              | PGL, liver and lymph nodes metastases | No | 250 mg/d (5/28) | No | NA         | Response³  | PR          | NA         | 5 cycles       | Grade 1 nausea                | (10)       |
| 8  | NA⁸     | SDHB          | Intact           | NA              | No | 150 mg/m² (5/28)/1, 200 mg/m² (5/28) | No | Response Normal⁵ | Baseline MNs < ULN | NA          | PMR         | 30 months       | NA¹          | (12)       |
| 9  | NA⁸     | SDHB          | NA               | NA              | NA⁸ | No | 150 mg/m² (5/28)/1, 200 mg/m² (5/28) | No | Stable     | Stable        | SD          | PMD         | 3 months       | NA¹          | (12)       |

(Continued)
| Pt | Sex/age | Gene mutation | MGMT methylation | MGMT expression | Location of mass | Prior treatment/ PFS (mo)/effect | TMZ doses/ cycles | Combination of other therapy | CgA response | MNs response | RECIST 1.1 | PERCIST 1.0 | Duration of TMZ | Side effect | References |
|----|---------|---------------|------------------|----------------|-----------------|-----------------------------------|-----------------|-------------------------------|--------------|--------------|-------------|--------------|-----------------|-------------|------------|
| 10 | NA      | SDHB          | NA               | Deficient      | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Response Normal               | NA           | PR           | PMR         | 13 months    | NA              | (12)        |
| 11 | NA      | SDHB          | NA               | Deficient      | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Response                       | Baseline MNs < ULN | SD          | SMD         | 8 months     | NA           | (12)        |
| 12 | NA      | SDHB          | NA               | Deficient      | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Response                       | Baseline MNs < ULN | PR          | PMR         | 26 months    | NA           | (12)        |
| 13 | NA      | SDHB          | NA               | Deficient      | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Response                       | Baseline MNs < ULN | PR          | PMR         | 21 months    | NA           | (12)        |
| 14 | NA      | SDHB          | NA               | NA             | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Progression                   | Progression     | PD          | PMD         | 3 months     | NA           | (12)        |
| 15 | NA      | SDHB          | NA               | Deficient      | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Response                       | Baseline MNs < ULN | PR          | PMR         | 22 months    | NA           | (12)        |
| 16 | NA      | SDHB          | NA               | Intact         | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Response                       | Stable         | SD          | SMD         | 7 months     | NA           | (12)        |
| 17 | NA      | SDHB          | NA               | NA             | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | NA                            | NA            | NA          | SMD         | 16 months    | NA           | (12)        |
| 18 | NA      | ND             | NA               | NA             | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Stable                        | Stable         | NA          | PMD         | 3 months     | NA           | (12)        |
| 19 | NA      | ND             | NA               | Intact         | NA              | No                                | 150 mg/m² / 200 mg/m² (5/28) | No              | Baseline                       | Baseline MNs < ULN | Stable      | PMD         | 9 months     | NA           | (12)        |

(Continued)
| Pt | Sex/age | Gene mutation | MGMTmethylation | MGMTexpression | Location of mass | Prior treatment/ PFS (mo)/effect | TMZ doses/cycles | Combination of other therapy | CgA response | MNs response | RECIST 1.1 | PERSIST 1.0 | Duration of TMZ | Side effect | References |
|----|---------|---------------|-----------------|----------------|-----------------|---------------------------------|-----------------|-----------------------------|--------------|---------------|------------|--------------|----------------|-------------|------------|
| 20 | NA      | NA            | Intact          | NA             | No              | 150 mg/m² (5/28)/1 200 mg/m² (5/28) | No             | Progression               | Progression  | SD            | NA         | 14 months   | NA            |             | (12)       |
| 21 | NA      | NA            | Intact          | NA             | No              | 150 mg/m² (5/28)/1 200 mg/m² (5/28) | No             | Stable                    | NA           | SD            | PMD        | 4 months    | NA            |             | (12)       |
| 22 | NA      | NA            | NA              | NA             | No              | 150 mg/m² (5/28)/1 200 mg/m² (5/28) | No             | NA                        | NA           | NA            | NA         | 1 months    | NA            |             | (12)       |
| 23 | F/41    | ND            | Yes             | Deficient      | Soft tissues and bone metastases | Sunitinib/3/PD | 150 mg/m² (5/28)/1 200 mg/m² (5/28) | No           | NA                        | Response     | PR            | NA         | Grade 1 nausea | This case   |             |            |

2 Median age of the 15 patients is 42.6 years old (range: 26–81), including 12 male and 3 female.
3 Not found gene mutation of SDHB, SDHD, SDHC, SDHA, VHL, NF1, RET, TMEM127, and MAX.
4 MGMT-intact tumors were defined by the presence of more than 20% positive tumor cells. MGMT deficient tumors were defined by the complete absence of positive tumor cells or by the presence of <20% positive cells.
5 The patient stopped the therapy due to side effect.
6 The patient weighed 115lb.
7 Complete response with normalization of CgA or MNs.
8 The detail data are not available from the original paper.
9 Response was defined as a CgA or MNs concentration following treatment that was 50% lower than that of baseline concentration.
10 Progression was defined as a CgA or MNs concentration following treatment that was 50% higher than that of baseline concentration.
11 CgA < 2 ULN or MNs < ULN is regarded as normal. And the biochemical response was not assessed in this case.
12 The 15 patients had bone (12 cases), lymph nodes (11 cases), liver (6 cases), and lung metastases (5 cases).
13 Three out of the 15 patients experienced Grade 3 toxicities, including lymphopenia (2 cases) and hypertension (1 case). Grade 1 or 2 toxicities were digestive problems (8 cases), anaemia (7 cases), asthenia (7 cases), and constipation (3 cases).
PR, Partial response; SD, Stable Disease; PD, Progressive Disease; PMR, Partial Metabolic Response; SMD, Stable Metabolic Disease; PMD, Progressive Metabolic Disease; NA, Not available; ND, Not found; ULN, Upper normal limit; PCC, Pheochromocytoma; PGL, Paraganglioma; TMZ, Temozolomide.
activity of MGMT, thus enhancing the effect of TMZ on DNA replication. Although the combination of TMZ and capcitabine is recommended for the treatment of pancreatic neuroendocrine neoplasms (29), it remains unknown whether the combination strategy works better than TMZ monotherapy in MPP patients. Prospective clinical trials are warranted.

In our patient, tumors shrank markedly after 3 cycles of TMZ therapy, suggesting it responded quickly to TMZ, which is consistent with the previous reports. In these papers, PR or partial metabolic response (PMR) usually occurs within 3–5 months following TMZ therapy. In the 23 patients, 12 patients and 4 patients took the drug for more than 1 and 2 years, respectively, for a maximum time period of 30 months, and some patients continued to take the drug at the end of the study (10–15). The long-term tolerability of TMZ monotherapy may be better than that of CVD therapy. Severe TMZ-related side effects are uncommon. Only 4 out of the 23 (17.4%) patients experienced Grade 3 toxicities, including lymphopenia (3 cases) and hypertension (1 case) (10–15).

CVD is the most active chemotherapy regimen for the treatment of MPP. A meta-analysis involving 50 MPP patients showed that the effective rate of CVD, in terms of tumor volume, was 55% (7). A recent retrospective study showed that, in 12 MPP patients with SDHB gene mutation, all patients had tumor reduction (12–100% by RECIST) upon CVD (6), which suggests CVD therapy probably works better in patients with SDHB mutation. However, CVD is not effective in all patients with SDHB mutation (patient 1 and patient 2 in Table 1). Their condition aggravated after CVD therapy but responded well to subsequent TMZ treatment. Due to the lack of prospective randomized clinical trials that compare the effects of CVD and TMZ, it is not sure which strategy is better. Previous studies seemed to show that TMZ was at least as effective as CVD regimen, and superior to CVD in that it has less side effects and is more convenient to use. In 2019, NCCN recommended both CVD regimen and TMZ for the treatment of MPP (5).

CONCLUSIONS

We present here a MPP patient who responded remarkably well to TMZ therapy. Globally, only 26 cases of MPP treated with TMZ have been described so far. Overall, TMZ is effective and safe in patients with MPP, and is more effective in patients with SDHB-related MPP. Measurement of MGMT expression might help assess the tumor sensitivity to TMZ but this still needs to be systematically investigated. Whether patients without MGMT methylation could also benefit from TMZ therapy remains unclear and should be further explored.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

Written informed consent was obtained for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

AT is the first author for this case report, and she contributed to the concept and design for the study. YL is the corresponding author supervising this work. ML, YC, XM, and HW contributed to the manuscript preparation. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

This project was supported by Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS-I2M) 2017-I2M-1-001 and National Key Program of Clinical Science of China (81770427).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2020.00061/full#supplementary-material

REFERENCES

1. Hescot S, Lebouilleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. (2013) 98:4006–12. doi: 10.1210/jc.2013-1907

2. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol. (2014) 80:487–501. doi: 10.1111/cen.12341

3. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [117m]Lu-DOTA0,Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. (2006) 47:1599–606.

4. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Lebouilleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. (2012) 97:4040–50. doi: 10.1210/jc.2012-2356

5. Shah M, Goldner W, Benson A, Berglind E, Berlin J, Blaszkowsky L, et al. NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors. J Natl Compr Canc Netw. (2019).

6. Jawed I, Velarde M, Därr R, Wolf KI, Adams K, Venkatesan AM, et al. Continued tumor reduction of metastatic pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy. Cell Mol Neurobiol. (2018) 38:1099–106. doi: 10.1007/s10571-018-0579-4

7. Niemeijer ND, Alblass G, van Hulsteijn LT, ekkers OM, Corssmit EP, Chemotherapy with cyclophosphamide, vincristine and dacarbazine for
malignant paranglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol. (2014) 81:642–51. doi: 10.1111/cen.12542
8. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. (2006) 24:401–6. doi: 10.1200/JCO.2005.03.6046
9. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. (2007) 13:2986–91. doi: 10.1158/1078-0432.CCR-06-2053
10. Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treatment of malignant paranglioma: a preliminary report. Horm Metab Res. (2009) 41:703–6. doi: 10.1055/s-0029-1224135
11. Nozières C, Walter T, Joly MO, Giraud S, Scoazec JY, Borson-Chazot F, et al. A SDHB malignant paranglioma with dramatic response to temozolomide–capcitabine. Eur J Endocrinol. (2012) 166:1107–11. doi: 10.1530/EJE-11-1098
12. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. (2014) 135:2711–20. doi: 10.1002/ijc.28913
13. Díaz-Castellanos MA, Gómez de Las Heras KV, Díaz-Redondo T, González-Flores E, Albíñana V, Botella LM. Case report: propranolol increases the therapeutic response to temozolomide in a patient with metastatic paranglioma. F1000Res. (2017) 6:2087. doi: 10.12688/F1000research.13185.1
14. Tena I, Gupta G, Tajahuerce M, Benavent M, Cifrián M, Falcon A, et al. Successful second-line metronomic temozolomide in metastatic paranglioma: case reports and review of the literature. Clin Med Insights Oncol. (2018) 12:1–9. doi: 10.1177/1179554918763367
15. Ferrara AM, Lombardi G, Pambuku A, Meringolo D, Bertorelle R, Nardin M, et al. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paranglioma. Anticancer Drugs. (2018) 29:102–5. doi: 10.1097/CAD.0000000000001278
16. Dahlrot RH, Larsen P, Boldt HB, Kreutzfeldt MS, Hansen S, Hjelmborg JB, et al. Posttreatment effect of MGMT methylation level on glioblastoma survival. J Neuropathol Exp Neurol. (2019) 78:633–40. doi: 10.1093/jnen/nlz032
17. Björklund P, Pacak K, Crona J. Precision medicine in pheochromocytoma and paranglioma: current and future concepts. J Intern Med. (2016) 280:559–73. doi: 10.1111/joim.12507
18. Crona J, Taieb D, Pacak K. New Perspectives on pheochromocytoma and paranglioma: toward a molecular classification. Endocr Rev. (2017) 38:489–515. doi: 10.1210/er.2017-00062
19. Neumann HPH, Young WF, Eng C. Pheochromocytoma and paranglioma. N Engl J Med. (2019) 381:552–65. doi: 10.1056/NEJMra1806651
20. Mestier L, Evrard C, Boissieu P, de Boissieu P, Hentic O, Croix J, et al. Temozolomide alone or combined to capcitabine for the treatment of advanced pancreatic NET. Neuroendocrinology. (2020) 110:83–91. doi: 10.1159/000500862
21. Bengtsson D, Schroeder HD, Berinder K, Maiter D, Hoybye C, Ragnarsson O, et al. Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine. (2018) 62:737–9. doi: 10.1007/s12260-018-1751-9
22. Zhang J, Stevens ME, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. (2012) 5:102–14. doi: 10.2174/1874467211205010102
23. Thomas A, Tanaka M, Trepel J, Reinhold WC, Rajapakse VN, Pommier Y. Temozolomide in the era of precision medicine. Cancer Res. (2017) 77:823–6. doi: 10.1158/0008-5472.CAN-16-2983
24. de Cubas A, Kopershoek E, Inglada-Pérez L, Letouzé E, Currás-Freixes M, Fernández A, et al. DNA methylation profiling in pheochromocytoma and paranglioma reveals diagnostic and prognostic markers. Clin Cancer Res. (2015) 21:3020–30. doi: 10.1158/1078-0432.CCR-14-2804
25. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paranglioma. Cancer Cell. (2017) 31:181–93. doi: 10.1016/j.ccell.2017.01.001
26. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. (2017) 18:315–29. doi: 10.1016/S1470-2045(17)30194-8
27. Hegi ME, Diserens AC, Gorlia T, Hamou ME, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. (2005) 352:997–1003. doi: 10.1056/NEJMoa043331
28. Koumarianou A, Kals tas G, Kulke MH, Oberg K, Strosberg JR, Spada F, et al. Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects. Neuroendocrinology. (2015) 101:274–88. doi: 10.1159/000430816
29. Lu Y, Zhao Z, Wang J, Lv W, Lu L, Fu W, et al. Safety and efficacy of combining capcitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis. Medicine. (2018) 97:e12784. doi: 10.1097/MD.00000000000012784

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Tong, Li, Cui, Ma, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which do not comply with these terms.